Tango Therapeutics (NASDAQ:TNGX) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Contrast

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Tango Therapeutics (NASDAQ:TNGX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Earnings & Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Tango Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.78	$363.05 million	($1.41)	-24.09
Tango Therapeutics	$62.38 million	69.24	-$101.59 million	($1.37)	-18.60

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Tango Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Lakefront Biotherapeutics American Depositary Shares and Tango Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Tango Therapeutics	2	2	13	0	2.65

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, suggesting a potential upside of 4.50%. Tango Therapeutics has a consensus target price of $45.54, suggesting a potential upside of 78.67%. Given Tango Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Institutional & Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Tango Therapeutics	N/A	-30.34%	-28.28%

Summary

Tango Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 13 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.